Quest Diagnostics DGX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $393M-6.4% | $420M-2.8% | $432M+35.4% | $319M+69.7% | $188M-65.8% | ||
| $1.59B+12.7% | $1.41B-3.3% | $1.46B+2.6% | $1.42B+1.1% | $1.4B+7.7% | ||
| $225M+19.0% | $189M+1.6% | $186M-0.5% | $187M-1.1% | $189M+0.5% | ||
| $361M0.0% | $361M+8.4% | $333M+22.0% | $273M-7.1% | $294M-16.2% | ||
| $2.57B+7.9% | $2.38B-1.2% | $2.41B+9.5% | $2.2B+5.9% | $2.08B-13.3% | ||
| $2.19B-0.6% | $2.2B+2.7% | $2.15B+1.2% | $2.12B+1.0% | $2.1B-0.7% | ||
| $691M+5.2% | $657M+1.2% | $649M-0.9% | $655M-0.2% | $656M+0.8% | ||
| $9.12B+2.0% | $8.95B+0.5% | $8.9B+0.2% | $8.88B+0.4% | $8.85B-0.1% | ||
| $1.72B+5.0% | $1.64B-1.6% | $1.66B-2.6% | $1.71B-1.1% | $1.73B-2.2% | ||
| $256M-5.2% | $270M-8.8% | $296M+9.2% | $271M+4.2% | $260M+2.0% | ||
| $134M-1.5% | $136M-0.7% | $137M+0.7% | $136M+1.5% | $134M+8.9% | ||
| $16.67B+2.8% | $16.23B+0.2% | $16.2B+1.4% | $15.97B+1.1% | $15.8B-2.2% | ||
| $1.5B-6.3% | $1.6B+9.8% | $1.46B+8.0% | $1.35B+6.5% | $1.27B-9.1% | ||
| $503M-0.2% | $504M0.0% | $504M0.0% | $504M+50,300% | $1M-99.8% | ||
| $174M0.0% | $174M+0.6% | $173M+1.2% | $171M-1.2% | $173M0.0% | ||
| $2.18B-4.4% | $2.28B+6.7% | $2.13B+5.4% | $2.02B+40.5% | $1.44B-33.6% | ||
| $5.16B-0.2% | $5.17B-0.1% | $5.17B0.0% | $5.17B-11.8% | $5.86B+4.3% | ||
| $574M+6.9% | $537M+0.6% | $534M-1.1% | $540M+0.4% | $538M+0.6% | ||
| $1.02B+6.8% | $957M-2.5% | $982M+10.3% | $890M-2.9% | $917M-2.2% | ||
| $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | ||
| $2.35B-1.4% | $2.38B+1.1% | $2.36B+1.0% | $2.33B+1.0% | $2.31B-2.2% | ||
| $10.15B+1.6% | $9.99B+1.6% | $9.84B+1.6% | $9.68B+2.0% | $9.49B+1.4% | ||
| -$43M-59.3% | -$27M+32.5% | -$40M-150% | -$16M+80.7% | -$83M+5.7% | ||
| $5.09B-1.7% | $5.18B+5.8% | $4.9B+2.6% | $4.77B-0.4% | $4.79B-1.4% | ||
| $79M-1.3% | $80M-1.2% | $81M0.0% | $81M0.0% | $81M-2.4% | ||
| $300M+733% | $36M-2.7% | $37M0.0% | $37M+12.1% | $33M-5.7% | ||
| $7.37B+2.7% | $7.17B-1.2% | $7.26B+0.4% | $7.23B+4.3% | $6.93B+2.2% | ||
| $16.67B+2.8% | $16.23B+0.2% | $16.2B+1.4% | $15.97B+1.1% | $15.8B-2.2% | ||
| $256M-5.2% | $270M-8.8% | $296M+9.2% | $271M+4.2% | $260M+2.0% | ||
| $691M+5.2% | $657M+1.2% | $649M-0.9% | $655M-0.2% | $656M+0.8% | ||
| $1.72B+5.0% | $1.64B-1.6% | $1.66B-2.6% | $1.71B-1.1% | $1.73B-2.2% | ||
| $691M+5.2% | $657M+1.2% | $649M-0.9% | $655M-0.2% | $656M+0.8% | ||
| $256M-5.2% | $270M-8.8% | $296M+9.2% | $271M+4.2% | $260M+2.0% | ||
| $691M+5.2% | $657M+1.2% | $649M-0.9% | $655M-0.2% | $656M+0.8% | ||
| $256M-5.2% | $270M-8.8% | $296M+9.2% | $271M+4.2% | $260M+2.0% | ||
| $1.5B-6.3% | $1.6B+9.8% | $1.46B+8.0% | $1.35B+6.5% | $1.27B-9.1% | ||
| $5.16B-0.2% | $5.17B-0.1% | $5.17B0.0% | $5.17B-11.8% | $5.86B+4.3% | ||
| $2.35B-1.4% | $2.38B+1.1% | $2.36B+1.0% | $2.33B+1.0% | $2.31B-2.2% | ||
| $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | $2M0.0% | ||
| $5.09B-1.7% | $5.18B+5.8% | $4.9B+2.6% | $4.77B-0.4% | $4.79B-1.4% | ||
| $134M-1.5% | $136M-0.7% | $137M+0.7% | $136M+1.5% | $134M+8.9% | ||
| $5.16B-0.2% | $5.17B-0.1% | $5.17B0.0% | $5.17B-11.8% | $5.86B+4.3% | ||
| $300M+733% | $36M-2.7% | $37M0.0% | $37M+12.1% | $33M-5.7% | ||
| $79M-1.3% | $80M-1.2% | $81M0.0% | $81M0.0% | $81M-2.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Quest Diagnostics's total assets?
- Quest Diagnostics (DGX) holds $16.7B in total assets, up 5.5% year over year.
- How much debt does Quest Diagnostics have?
- Quest Diagnostics carries $6.4B in total debt against $7.4B of shareholders' equity, a debt-to-equity ratio of 0.87.
- How much cash does Quest Diagnostics have?
- Quest Diagnostics holds $393.0M in cash and equivalents.
- Can Quest Diagnostics cover its short-term obligations?
- Its current ratio is 1.18 — current assets exceed current liabilities.
- Where does Quest Diagnostics's balance sheet data come from?
- Every line is extracted from Quest Diagnostics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
